𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Use of the hypoxic cell sensitizer etanidazole (SR-2508) with intravenous melphalan and prednisone in the treatment of multiple myeloma: A pharmacokinetic study

✍ Scribed by Lawrence N. Shulman; Lori Buswell; Leslie A. Kalish; C. Norman Coleman

Publisher
Elsevier Science
Year
1994
Tongue
English
Weight
422 KB
Volume
29
Category
Article
ISSN
0360-3016

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

The use of low-dose prednisone and melph
The use of low-dose prednisone and melphalan in the treatment of poor-risk patients with multiple myeloma
✍ Cuttner, Janet ;Wasserman, L. R. ;Martz, Georg ;Sonntag, Roland W. ;Kyle, Robert πŸ“‚ Article πŸ“… 1975 πŸ› John Wiley and Sons 🌐 English βš– 416 KB

## Abstract A study was designed to evaluate the effectiveness of prednisone therapy in poor‐risk patients with multiple myeloma. Patients were treated with melphalan alone or in combination with prednisone at doses of either 0.6 mg/kg or 0.3 mg/ kg. The group of patients receiving melphalan and pr

Comparison of melphalan and prednisone w
Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma : Results of Eastern Cooperative Oncology Group study E2479
✍ Martin M. Oken; David P. Harrington; Neil Abramson; Robert A. Kyle; William Knos πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 97 KB πŸ‘ 1 views

## METHODS. Four hundred seventy-nine previously untreated patients with multiple myeloma from 23 ECOG institutions were enrolled. Treatment, assigned by ran-1 The Virginia Piper Cancer Institute and the Unidomization, consisted of either 4-week cycles of MP or 5-week cycles of VBCMP.